MEDIFAST INC
$ 11.92
-1.81%
11 Jun - close price
- Market Cap 132,540,000 USD
- Current Price $ 11.92
- High / Low $ 12.27 / 11.87
- Stock P/E N/A
- Book Value 19.28
- EPS -1.82
- Next Earning Report 2026-08-10
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.04 %
- ROE -0.10 %
- 52 Week High 15.46
- 52 Week Low 9.22
About
Medifast, Inc. manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutrition products in the United States and Asia-Pacific. The company is headquartered in Baltimore, Maryland.
Analyst Target Price
$12.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-04 | 2026-02-17 | 2025-11-03 | 2025-08-04 | 2025-04-28 | 2025-02-18 | 2024-11-04 | 2024-08-05 | 2024-04-29 | 2024-02-20 | 2023-11-06 | 2023-08-07 |
| Reported EPS | -0.19 | -1.65 | -0.21 | 0.22 | -0.07 | 0.1 | 0.35 | 0.92 | 0.66 | 0.55 | 2.12 | 2.77 |
| Estimated EPS | -0.52 | -0.45 | -0.36 | -0.19 | -0.25 | 0.2424 | -0.28 | 0.39 | 0.8 | 0.96 | 1.07 | 1.44 |
| Surprise | 0.33 | -1.2 | 0.15 | 0.41 | 0.18 | -0.1424 | 0.63 | 0.53 | -0.14 | -0.41 | 1.05 | 1.33 |
| Surprise Percentage | 63.4615% | -266.6667% | 41.6667% | 215.7895% | 72% | -58.7459% | 225% | 135.8974% | -17.5% | -42.7083% | 98.1308% | 92.3611% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-10 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.65 |
| Currency | USD |
Previous Dividend Records
| Nov 2023 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2023-11-07 | None | None | None | None | None | None | None | None | None |
| Amount | $1.65 | $1.65 | $1.65 | $1.64 | $1.64 | $1.64 | $1.64 | $1.42 | $1.42 | $1.42 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MED
2026-06-11 11:10:40
The article discusses the impact of perimenopause and menopause on metabolic health and weight management, highlighting how declining estrogen accelerates visceral fat accumulation and lean muscle loss. It emphasizes that traditional weight loss methods focusing solely on scale weight are ineffective during this period. The article promotes OPTAVIA's clinically supported programs, which target visceral fat reduction and lean mass preservation, alongside the benefits of coaching for better outcomes.
2026-06-11 10:39:21
The article discusses the metabolic challenges women face during perimenopause and menopause, emphasizing that standard weight management approaches often fail to address accelerated visceral fat accumulation and lean muscle loss. It highlights OPTA VIA's clinically supported programs, which focus on reducing visceral fat while preserving lean mass, and stresses the importance of coaching during these hormonal transitions. The piece explains why body composition metrics are more crucial than scale weight for women over 40 and outlines what a metabolically appropriate program entails.
2026-06-11 10:39:21
This article examines what differentiates truly science-backed subscription health programs in the $31 billion weight loss and weight management market. It highlights that terms like "clinically studied" lack standardized definitions, emphasizing the importance of specific measurement tools like DXA scanning over simple scale weight, and high study completion rates in verifying program outcomes. OPTAVIA is presented as an example of a program that utilizes peer-reviewed randomized controlled trials and DXA body composition assessment to demonstrate its effectiveness, including significant lean mass retention and fat loss.
2026-06-04 06:09:53
Medifast (MED) announced that its Chief Legal Officer and Corporate Secretary, Jason L. Groves, Esq., resigned on May 29, 2026, and entered into a separation agreement. The company stated his departure was not due to disagreements or operational issues and has initiated a search for a permanent replacement. Analysts currently rate MED stock as a Hold with a $12.00 price target.
2026-06-01 13:15:05
Medifast (NYSE: MED) announced the resignation of its Chief Legal Officer and Corporate Secretary, Jason L. Groves, effective Thursday. Groves will receive a one-time severance payment. The company has begun the search for his replacement, noting that his departure was not due to any disagreement with Medifast's operations or policies.
2026-06-01 12:59:05
MEDIFAST INC (MED) has filed an 8-K report announcing the resignation of Jason L. Groves, Esq., Chief Legal Officer & Corporate Secretary, effective May 29, 2026. He will receive a one-time severance payment equal to one month of his annual base salary. The company stated his departure was not due to any disagreements and it has begun searching for a replacement.
